Vascular complications and changes in body mass index in Japanese type 2 diabetic patients with abdominal obesity
详细信息 查看全文
- 作者：Hirofumi Nagao (1)
Susumu Kashine (2)
Hitoshi Nishizawa (1)
Takuya Okada (3)
Takekazu Kimura (1)
Ayumu Hirata (1)
Shiro Fukuda (1)
Junji Kozawa (1)
Norikazu Maeda (1)
Tetsuhiro Kitamura (1)
Tetsuyuki Yasuda (1)
Kohei Okita (1)
Toshiyuki Hibuse (2)
Mamiko Tsugawa (3)
Akihisa Imagawa (1)
Tohru Funahashi (4)
Iichiro Shimomura (1) - 关键词：Abdominal obesity ; Type 2 diabetes ; Waist circumference ; Visceral fat accumulation ; Body mass index ; Cardiovascular disease
- 刊名：Cardiovascular Diabetology
- 出版年：2013
- 出版时间：December 2013
- 年：2013
- 卷：12
- 期：1
- 全文大小：215KB
- 参考文献：1. World Health Organization: / Obesity and overweight; WHO Fact Sheet No311. 2013. http://www.who.int/mediacentre/factsheets/fs311/en/index.html
2. Shaw JE, Sicree RA, Zimmet PZ: Global estimates of the prevalence of diabetes for 2010 and 2030. / Diabetes Res Clin Pract 2010, 87:4-4. CrossRef
3. Yoon KH, Lee JH, Kim JW, Cho JH, Choi YH, Ko SH, Zimmet P, Son HY: Epidemic obesity and type 2 diabetes in Asia. / Lancet 2006, 368:1681-688. CrossRef
4. Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, Hu FB: Diabetes in Asia. epidemiology, risk factors, and pathophysiology. / JAMA 2009, 301:2129-140. CrossRef
5. Fujimoto WY: Overview of non-insulin-dependent diabetes mellitus (NIDDM) in different population groups. / Diabet Med 1996, 13:S7-S10.
6. Fujimoto WY, Akanuma Y, Kanazawa Y, Mashiko S, Leonetti D, Wahl P: Plasma insulin levels in Japanese and Japanese-American men with type 2 diabetes may be related to the occurrence of cardiovascular disease. / Diabetes Res Clin Pract 1989, 6:121-27. CrossRef
7. Huxley R, James WP, Barzi F, Patel JV, Lear SA, Suriyawongpaisal P, Janus E, Caterson I, Zimmet P, Prabhakaran D, Reddy S, Woodward M: Obesity in Asia Collaboration. Ethnic comparisons of the cross-sectional relationships between measures of body size with diabetes and hypertension. / Obes Rev 2008, 9:53-1. CrossRef
8. Nagaya T, Yoshida H, Takahashi H, Kawai M: Increases in body mass index, even within non-obese levels, raise the risk for Type 2 diabetes mellitus: a follow-up study in a Japanese population. / Diabet Med 2005, 22:1107-111. CrossRef
9. Oh SW, Shin SA, Yun YH, Yoo T, Huh BY: Cut-off point of BMI and obesity-related comorbidities and mortality in middle-aged Koreans. / Obes Res 2004, 12:2031-040. CrossRef
10. Neeland IJ, Ayers CR, Rohatgi AK, Turer AT, Berry JD, Das SR, Vega GL, Khera A, McGuire DK, Grundy SM, de Lemos JA: Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults. / Obesity (Silver Spring) 2012. Epub ahead of print
11. Iwahashi H, Okauchi Y, Ryo M, Noguchi M, Morita S, Kishida K, Okita K, Ohira T, Funahashi T, Nakamura T, Imagawa A, Shimomura I: Insulin-secretion capacity in normal glucose tolerance, impaired glucose tolerance, and diabetes in obese and non-obese Japanese patients. / J Diabetes Invest 2012, 3:271-75. CrossRef
12. Okauchi Y, Nishizawa H, Funahashi T, Ogawa T, Noguchi M, Ryo M, Kihara S, Iwahashi H, Yamagata K, Nakamura T, Shimomura I, Matsuzawa Y: Reduction of visceral fat is associated with decrease in the number of metabolic risk factors in Japanese men. / Diabetes Care 2007, 30:2392-394. CrossRef
13. Kissebah AH, Vydelingum N, Murray R, Evans DJ, Hartz AJ, Kalkhoff RK, Adams PW: Relation of body fat distribution to metabolic complications of obesity. / J Clin Endocrinol Metab 1982, 54:254-60. CrossRef
14. Nakamura T, Tokunaga K, Shimomura I, Nakamura T, Tokunaga K, Shimomura I, Nishida M, Yoshida S, Kotani K, Islam AH, Keno Y, Kobatake T, Nagai Y, Fujioka S, Tarui S, Matsuzawa Y: Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men. / Atherosclerosis 1994, 107:239-46. CrossRef
15. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T, Yamashita S, Miura M, Fukuda Y, Takemura K, Tokunaga K, Matsuzawa Y: Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. / Nat Med 1996, 2:800-03. CrossRef
16. Hotmisligli GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM: Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. / J Clin Invest 1995, 95:2409-415. CrossRef
17. Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, Knowler WC, Krakoff J: Adiponectin and development of type 2 diabetes in the Pima Indian population. / Lancet 2002, 360:57-8. CrossRef
18. Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, Nagai M, Matsuzawa Y, Funahashi T: Adiponectin as a biomarker of the metabolic syndrome. / Circ J 2004, 68:975-81. CrossRef
19. Mallamaci F, Zoccali C, Cuzzola F, Tripepi G, Cutrupi S, Parlongo S, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y: Adiponectin in essential hypertension. / J Nephrol 2002, 15:507-11.
20. Mohammadreza B, Farzad H, Davoud K, Fereidoun Prof AF: Prognostic significance of the complex “Visceral Adiposity Index-vs. simple anthropometric measures: Tehran lipid and glucose study. / Cardiovasc Diabetol 2012, 11-0.
21. Hiuge-Shimizu A, Kishida K, Funahashi T, Ishizaka Y, Oka R, Okada M, Suzuki S, Takaya N, Nakagawa T, Fukui T, Fukuda H, Watanabe N, Yoshizumi T, Nakamura T, Matsuzawa Y, Yamakado M, Shimomura I: Absolute value of visceral fat area measured on computed tomography scans and obesity-related cardiovascular risk factors in large-scale Japanese general population (the VACATION-J study). / Ann Med 2012, 44:82-2. CrossRef
22. New criteria for ‘obesity disease-in Japan. Examination Committee of Criteria for ‘Obesity Disease-in Japan; Japan Society for the Study of Obesity: New criteria for ‘obesity disease-in Japan. Examination Committee of Criteria for ‘Obesity Disease-in Japan. / Circ J 2002, 66:987-92. CrossRef
23. Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, Daida H, Biro S, Hirobe K, Funahashi T, Yokote K, Yokode M: Metabolic syndrome. / J Atheroscler Thromb 2008, 15:1-. CrossRef
24. Kashiwagi A, Kasuga M, Araki E, Oka Y, Hanafusa T, Ito H, Tominaga M, Oikawa S, Noda M, Kawamura T, Sanke T, Namba M, Hashiramoto M, Sasahara T, Nishio Y, Kuwa K, Ueki K, Takei I, Umemoto M, Murakami M, Yamakado M, Yatomi Y, Ohashi H: International clinical harmonization of glycated hemoglobin in Japan : From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. / J Diabetes Invest 2012, 3:39-0. CrossRef
25. Yki-J?rvinen H, Esko N, Eero H, Marja-Riitta T: Clinical benefits and mechanisms of a sustained response to intermittent insulin therapy in type 2 diabetic patients with secondary drug failure. / Am J Med 1988, 84:185-2. CrossRef
26. Hiatt WR: Medical Treatment of Peripheral Arterial Disease and Claudication. / N Engl J Med 2001, 344:1608-621. CrossRef
27. Mohler ER 3rd: Peripheral arterial disease: identification and implications. / Arch Intern Med 2003, 163:2306-314. CrossRef
28. Smith U, Hammersten J, Bj?rntorp P, Kral JG: Regional differences and effect of weight reduction on human fat cell metabolism. / Eur J Clin Invest 1979, 9:327-32. CrossRef
29. Mittelman SD, Van Citters GW, Kirkman EL, Bergman RN: Extreme insulin resistance of the central adipose depot in vivo. / Diabetes 2002, 51:755-61. CrossRef
30. Londos C, Brasaemle DL, Schultz CJ, Adler-Wailes DC, Levin DM, Kimmel AR, Rondinone CM: On the control of lipolysis in adipocytes. / Ann N Y Acad Sci 1999, 892:155-68. CrossRef
31. Kuriyama H, Yamashita S, Shimomura I, Funahashi T, Ishigami M, Aragane K, Miyaoka K, Nakamura T, Takemura K, Man Z, Toide K, Nakayama N, Fukuda Y, Lin MC, Wetterau JR, Matsuzawa Y: Enhanced expression of hepatic acyl-coenzyme A synthetase and microsomal triglyceride transfer protein messenger RNAs in the obese and hypertriglyceridemic rat with visceral fat accumulation. / Hepatology 1998, 27:557-62. CrossRef
32. White DA, Bennett AJ, Billett MA, Salter AM: The assembly of triacylglycerol-rich lipoproteins: an essential role for the microsomal triacylglycerol transfer protein. / Br J Nutr 1998, 80:219-29.
33. Adeli K, Taghibiglou C, Van Iderstine SC, Lewis GF: Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistance. / Trends Cardiovasc Med 2001, 11:170-76. CrossRef
34. Kuriyama H, Shimomura I, Kishida K, Kondo H, Furuyama N, Nishizawa H, Maeda N, Matsuda M, Nagaretani H, Kihara S, Nakamura T, Tochino Y, Funahashi T, Matsuzawa Y: Coordinated regulation of fat-specific and liver-specific glycerol channels, aquaporin adipose and aquaporin 9. / Diabetes 2002, 51:2915-921. CrossRef
35. Maeda N, Funahashi T, Shimomura I: Metabolic impact of adipose and hepatic glycerol channels aquaporin 7 and aquaporin 9. / Nat Clin Pract Endocrinol Metab 2008, 4:627-4.
36. Spiegelman BM, Flier JS: Obesity and the regulation of energy balance. / Cell 2001, 23:531-43. CrossRef
37. Matsuzawa Y, Funahashi T, Nakamura T: The concept of metabolic syndrome: contribution of visceral fat accumulation and its molecular mechanism. / J Atheroscler Thromb 2011, 18:629-39. CrossRef
38. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, Nagaretani H, Matsuda M, Komuro R, Ouchi N, Kuriyama H, Hotta K, Nakamura T, Shimomura I, Matsuzawa Y: PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. / Diabetes 2001, 50:2094-099. CrossRef
39. Kurata A, Nishizawa H, Kihara S, Maeda N, Sonoda M, Okada T, Ohashi K, Hibuse T, Fujita K, Yasui A, Hiuge A, Kumada M, Kuriyama H, Shimomura I, Funahashi T: Blockade of Angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation. / Kidney Int 2006, 70:1717-724. CrossRef
40. Hiuge A, Tenenbaum A, Maeda N, Benderly M, Kumada M, Fisman EZ, Tanne D, Matas Z, Hibuse T, Fujita K, Nishizawa H, Adler Y, Motro M, Kihara S, Shimomura I, Behar S, Funahashi T: Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level. / Arterioscler Thromb Vasc Biol 2007, 27:635-41. CrossRef
41. Inoue K, Maeda N, Kashine S, Fujishima Y, Kozawa J, Hiuge-Shimizu A, Okita K, Imagawa A, Funahashi T, Shimomura I: Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes. / Cardiovasc Diabetol 2011, 10:109. CrossRef
42. Fujishima Y, Maeda N, Inoue K, Kashine S, Nishizawa H, Hirata A, Kozawa J, Yasuda T, Okita K, Imagawa A, Funahashi T, Shimomura I: Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes. / Cardiovasc Diabetol 2012, 11:107. CrossRef
43. Yoshida Y, Hagura R, Hara Y, Sugasawa G, Akanuma Y: Risk factors for the development of diabetic retinopathy in Japanese type 2 diabetic patients. / Diabetes Res Clin Pract 2001, 51:195-03. CrossRef
44. Stratton IM, Kohner EM, Aldington SJ, Turner RC, Holman RR, Manley SE, Matthews DR, UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis. / Diabetologia 2001, 44:156-63. CrossRef
45. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. / N Engl J Med 1993, 329:977-86. CrossRef
46. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). / Lancet 1998, 352:837-53. CrossRef
47. Lee IT, Chiu YF, Hwu CM, He CT, Chiang FT, Lin YC, Assimes T, Curb JD, Sheu WH: Central obesity is important but not essential component of the metabolic syndrome for predicting diabetes mellitus in a hypertensive family-based cohort. Results from the Stanford Asia-pacific program for hypertension and insulin resistance (SAPPHIRe) Taiwan follow-up study. / Cardiovasc Diabetol 2012, 11:43. CrossRef
48. Nooyens AC, van Duijnhoven FJ, Verschuren WM, Boer JM, van der A DL: All-cause mortality risk of metabolically healthy abdominal obese individuals: The EPIC-MORGEN study. / Obesity (Silver Spring) 2013. Epub ahead of print - 作者单位：Hirofumi Nagao (1)
Susumu Kashine (2)
Hitoshi Nishizawa (1)
Takuya Okada (3)
Takekazu Kimura (1)
Ayumu Hirata (1)
Shiro Fukuda (1)
Junji Kozawa (1)
Norikazu Maeda (1)
Tetsuhiro Kitamura (1)
Tetsuyuki Yasuda (1)
Kohei Okita (1)
Toshiyuki Hibuse (2)
Mamiko Tsugawa (3)
Akihisa Imagawa (1)
Tohru Funahashi (4)
Iichiro Shimomura (1)
1. Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, 2-2 B-5, Yamada-oka, Suita, Osaka, 565-0871, Japan
2. Suita Municipal Hospital, 2-13-20, Katayamacho, Suita, Osaka, 564-0082, Japan
3. Ikeda Municipal Hospital, 3-1-18, Jonan, Ikeda, Osaka, 563-8510, Japan
4. Department of Metabolism and Atherosclerosis, Graduate School of Medicine, Osaka University, 2-2-B, Yamada-oka, Suita, Osaka, 565-0871, Japan
文摘
Background Although many Asian type 2 diabetic patients have been considered to be not obese and have low capacity of insulin secretion, the proportion of obese patients with visceral fat accumulation has increased in recent years. We found previously considerable number of Japanese non-obese subjects (body mass index (BMI) < 25 kg/m2) with visceral fat accumulation and multiple cardiovascular risk factors. The aim of the study was to investigate the difference in clinical features of type 2 diabetic patients with and without visceral fat accumulation, focusing on vascular complications and changes in BMI. Methods We enrolled 88 Japanese hospitalized type 2 diabetic patients. Abdominal obesity represented waist circumference (WC) of ?5 cm for males and ?0 cm for females (corresponding to visceral fat area of 100 cm2). Subjects were divided into two groups; with or without abdominal obesity. Results Hypertension, dyslipidemia and cardiovascular diseases were significantly more in the patients with abdominal obesity. The prevalence of cardiovascular disease in the non-obese patients (BMI < 25 kg/m2) with abdominal obesity were similar in obese patients (BMI ?5 kg/m2). The mean BMI of the patients with abdominal obesity was < 25 kg/m2 at 20 years of age, but reached maximum to more than 30 kg/m2 in the course. Furthermore, substantial portion of the type 2 diabetic patients (52% in males and 43% in females) were not obese at 20 year-old (BMI < 25 kg/m2), but developed abdominal obesity by the time of admission. Conclusion These results emphasize the need to control multiple risk factors and prevent atherosclerotic disease in patients with abdominal obesity. The significant weight gain after 20 years of age in patients with abdominal obesity stresses the importance of lifestyle modification in younger generation, to prevent potential development of type 2 diabetes and future atherosclerotic cardiovascular disease.